ライフサイエンスコーパス: compendia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 EX, and Clinical Pharmacology to the list of compendia.

2 dications to indications listed in specified compendia.

3 ts, synthetic data and various metazoan data compendia.

4 ns in both simulated datasets and microarray compendia.

5 largest source of variation in metazoan data compendia.

6 are program to refer to 3 existing published compendia, American Medical Association Drug Evaluations

7 ff-label uses recognized by established drug compendia and peer-reviewed literature.

8 asing calls to revise the list of acceptable compendia, as authorized in the statute.

9 For 1 indication, compendia citations did not increase between 2006 and 20

10 Compendia cited little of the available evidence, often

11 assessment, public and private payers, drug compendia, clinical research entities, statisticians, ac

12 ysis and visualization of expression data in compendia compiled from multiple laboratories.

13 These massive compendia comprise billions of measurements and provide

14 All versions of the normalized compendia constructed for each species are maintained an

15 n between 2006 and 2008, and completeness of compendia content and citations were assessed.

16 e it difficult to determine whether and when compendia content was updated.

17 Compendia differed in evidence cited, terminology, detai

18 or the 14 off-label indications studied, the compendia differed in the indications included and wheth

19 Oncologists rely on compendia for up-to-date access to evidence and reimburs

20 es (>20,000 genes) and very large microarray compendia (>10,000 conditions).

21 nce efforts to exploit growing drug response compendia in order to advance personalized therapy.

22 methods that leverage the heterogeneous data compendia in their entirety.

23 e components in diverse published expression compendia, including normal tissues and tumor samples.

24 chniques applied to enormous gene expression compendia into the hands of bench biologists.

25 Current compendia lack transparency, cite little current evidenc

26 ppropriate treatment, as reflected in timely compendia listings and reports of studies in the medical

27 tudies, have been extensively used to create compendia of genes that are preferentially expressed in

28 sion levels of known relevant genes in large compendia of microarray data.

29 To aid in the analysis of such large compendia of microarray experiments, we present Microarr

30 linical Validation of Drug Indications Using Compendia of Public Gene Expression Data".

31 Public compendia of sequencing data are now measured in petabyt

32 To this end, we compare two large compendia of transcriptional profiles of human and mouse

33 ds of patients and their clinical providers, compendia, payers, and policy makers, recommendations ar

34 The compendia's stated methods varied greatly from their act

35 Data Assessment: The compendia's stated methods, literature related to off-la

36 ision that explicitly prohibits inclusion of compendia that do not have a publicly transparent proces

37 rgets of genetic perturbations in microarray compendia, with up to a 24% improvement in sensitivity o

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。